Know Cancer

or
forgot password

The CALGB Lung Cancer Tissue Bank


N/A
18 Years
N/A
Open (Enrolling)
Both
Lung Cancer

Thank you

Trial Information

The CALGB Lung Cancer Tissue Bank


OBJECTIVES:

- Collect and store frozen specimens of tumor, involved lymph node (when available), and
grossly uninvolved adjacent lung tissues obtained from patients during surgical staging
or resection of lung cancer, for later molecular analysis.

- Collect and store frozen blood samples from these patients, as a source of reference
DNA to assess somatic mutations associated with tumor or preneoplastic "normal" lung
and to assess levels of circulating markers.

- Correlate these analyses with historical, clinical, pathological, and outcome
information.

OUTLINE: Grossly viable tumor and grossly normal lung tissue are identified and removed from
patient surgical specimens and cryopreserved until shipment to the CALGB Lung Cancer Tissue
Bank for future use in research. Blood specimens are obtained pre- or intra-operatively and
shipped immediately to the Tissue Bank.

Patients do not receive the results of the research.

PROJECTED ACCRUAL: Samples from approximately 100 patients per year will be collected for at
least 5 years.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Suspected or histologically confirmed lung cancer

- Undergoing surgical staging or resection of tumor at a CALGB Lung Cancer Tissue
Bank-approved institution

- No concurrent enrollment on clinical study CALG 140203, intraoperative sentinal node
mapping in non-small cell lung cancer

PATIENT CHARACTERISTICS:

- No known infectious disease (e.g., HIV, tuberculosis, or hepatitis B or C)

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Collection and storage of frozen specimens of tumor, involved lymph node (when available), and grossly uninvolved adjacent lung tissues obtained from patients during surgical staging or resection of lung cancer

Safety Issue:

No

Principal Investigator

David J. Sugarbaker, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Dana-Farber/Brigham and Women's Cancer Center

Authority:

Unspecified

Study ID:

CDR0000271323

NCT ID:

NCT00899782

Start Date:

July 2004

Completion Date:

Related Keywords:

  • Lung Cancer
  • non-small cell lung cancer
  • small cell lung cancer
  • Lung Neoplasms

Name

Location
Roswell Park Cancer Institute Buffalo, New York  14263
CCOP - Christiana Care Health Services Wilmington, Delaware  19899
Ellis Fischel Cancer Center at University of Missouri - Columbia Columbia, Missouri  65203
Veterans Affairs Medical Center - Asheville Asheville, North Carolina  28805
Fletcher Allen Health Care - University Health Center Campus Burlington, Vermont  05401
SUNY Upstate Medical University Hospital Syracuse, New York  13210
Rhode Island Hospital Comprehensive Cancer Center Providence, Rhode Island  02903
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute Boston, Massachusetts  02115
Masonic Cancer Center at University of Minnesota Minneapolis, Minnesota  55455
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis St. Louis, Missouri  63110
Cancer Institute of New Jersey at Cooper - Voorhees Voorhees, New Jersey  08043
Allegheny Cancer Center at Allegheny General Hospital Pittsburgh, Pennsylvania  15212
Tunnell Cancer Center at Beebe Medical Center Lewes, Delaware  19958
Union Hospital of Cecil County Elkton MD, Maryland  21921
Dana-Farber/Brigham and Women's Cancer Center Boston, Massachusetts  02115
Duke Cancer Institute Durham, North Carolina  27710
Miriam Hospital Providence, Rhode Island  02906
Alle-Kiski Medical Center Natrona Heights, Pennsylvania  15065
Forbes Regional Hospital Monroeville, Pennsylvania  15146